Literature DB >> 35723756

Animal venoms as a source of antiviral peptides active against arboviruses: a systematic review.

William Gustavo Lima1,2, César Quadros Maia3, Thayane Santos de Carvalho3, Gustavo Oliveira Leite4, Júlio César Moreira Brito5,6, Isabella Piassi Dias Godói5,7, Maria Elena de Lima8, Jaqueline Maria Siqueira Ferreira3.   

Abstract

Arthropod-borne viruses (arboviruses), such as Zika virus (ZIKV), chikungunya virus (CHIKV), dengue virus (DENV), yellow fever virus (YFV), and West Nile virus (WNV), are pathogens of global importance. Therefore, there has been an increasing need for new drugs for the treatment of these viral infections. In this context, antimicrobial peptides (AMPs) obtained from animal venoms stand out as promising compounds because they exhibit strong antiviral activity against emerging arboviral pathogens. Thus, we systematically searched and critically analyzed in vitro and in vivo studies that evaluated the anti-arbovirus effect of peptide derivatives from toxins produced by vertebrates and invertebrates. Thirteen studies that evaluated the antiviral action of 10 peptides against arboviruses were included in this review. The peptides were derived from the venom of scorpions, spiders, wasps, snakes, sea snails, and frogs and were tested against DENV, ZIKV, YFV, WNV, and CHIKV. Despite the high structural variety of the peptides included in this study, their antiviral activity appears to be associated with the presence of positive charges, an excess of basic amino acids (mainly lysine), and a high isoelectric point (above 8). These peptides use different antiviral mechanisms, the most common of which is the inhibition of viral replication, release, entry, or fusion. Moreover, peptides with virucidal and cytoprotective (pre-treatment) effects were also identified. In conclusion, animal-venom-derived peptides stand out as a promising alternative in the search and development of prototype antivirals against arboviruses.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35723756     DOI: 10.1007/s00705-022-05494-8

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.685


  30 in total

1.  Identification of a Potential Zika Virus Inhibitor Targeting NS5 Methyltransferase Using Virtual Screening and Molecular Dynamics Simulations.

Authors:  Felipe R S Santos; William G Lima; Eduardo H B Maia; Letícia C Assis; Danilo Davyt; Alex Gutterres Taranto; Jaqueline M S Ferreira
Journal:  J Chem Inf Model       Date:  2020-02-07       Impact factor: 4.956

2.  Serum lipid profile as a predictor of dengue severity: A systematic review and meta-analysis.

Authors:  William Gustavo Lima; Nayara Alves Souza; Simone Odília Antunes Fernandes; Valbert Nascimento Cardoso; Isabella Piassi Godói
Journal:  Rev Med Virol       Date:  2019-06-06       Impact factor: 6.989

3.  Animal venom studies: Current benefits and future developments.

Authors:  Yuri N Utkin
Journal:  World J Biol Chem       Date:  2015-05-26

Review 4.  Animal Venom Peptides: Potential for New Antimicrobial Agents.

Authors:  Muriel Primon-Barros; Alexandre José Macedo
Journal:  Curr Top Med Chem       Date:  2017       Impact factor: 3.295

Review 5.  From dengue to Zika: the wide spread of mosquito-borne arboviruses.

Authors:  Shivani Sukhralia; Mansi Verma; Shruthi Gopirajan; P S Dhanaraj; Rup Lal; Neeti Mehla; Chhaya Ravi Kant
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-09-28       Impact factor: 3.267

Review 6.  Pharmacophoric characteristics of dengue virus NS2B/NS3pro inhibitors: a systematic review of the most promising compounds.

Authors:  Camyla Alves Leonel; William Gustavo Lima; Michelli Dos Santos; Ariane Coelho Ferraz; Alex Gutterres Taranto; José Carlos de Magalhães; Luciana Lara Dos Santos; Jaqueline Maria Siqueira Ferreira
Journal:  Arch Virol       Date:  2017-11-16       Impact factor: 2.574

7.  Identification of Zika Virus NS2B-NS3 Protease Inhibitors by Structure-Based Virtual Screening and Drug Repurposing Approaches.

Authors:  Felipe R S Santos; Damiana A F Nunes; William G Lima; Danilo Davyt; Luciana L Santos; Alex G Taranto; Jaqueline M S Ferreira
Journal:  J Chem Inf Model       Date:  2019-12-31       Impact factor: 4.956

8.  Nifuroxazide as JAK2 inhibitor: A binding mode proposal and Hel cell proliferation assay.

Authors:  Marcela Oliveira Legramanti da Costa; Thais Fernanda Amorim Pavani; Angélica Nakagawa Lima; Ana Lígia Scott; Débora Felicia Vieira Ramos; Mariana Lazarini; Daniela Gonçales Galasse Rando
Journal:  Eur J Pharm Sci       Date:  2021-03-26       Impact factor: 4.384

Review 9.  Non-vector-borne transmission of Zika virus: A systematic review.

Authors:  Franca Grischott; Milo Puhan; Christoph Hatz; Patricia Schlagenhauf
Journal:  Travel Med Infect Dis       Date:  2016-07-15       Impact factor: 6.211

10.  The global distribution and burden of dengue.

Authors:  Samir Bhatt; Peter W Gething; Oliver J Brady; Jane P Messina; Andrew W Farlow; Catherine L Moyes; John M Drake; John S Brownstein; Anne G Hoen; Osman Sankoh; Monica F Myers; Dylan B George; Thomas Jaenisch; G R William Wint; Cameron P Simmons; Thomas W Scott; Jeremy J Farrar; Simon I Hay
Journal:  Nature       Date:  2013-04-07       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.